ArticleDementia and geriatric cognitive disorders extra
Recovery of Dementia Syndrome following Treatment of Brain Inflammation.
Article in Dementia and geriatric cognitive disorders extra. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 50 citations in OpenAlex.
- Bronchitis, COPD, and pneumonia after viral endemic of patients with leprosy on Sorok Island in South Korea.Naunyn-Schmiedeberg's archives of pharmacology · 2023Trial
- Aggravating mechanisms from COVID-19.Virology journal · 2024Review
- Treatment mechanism of immune triad from the repurposing drug against COVID-19.Translational medicine of aging · 2023Review
- COVID-19 Molecular Pathophysiology: Acetylation of Repurposing Drugs.International journal of molecular sciences · 2022Review
- The link between cutaneous inflammation and cognitive impairment.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Review
- Article
- The listed, delisted, and sustainability of therapeutic medicines for dementia patients: the study is specific to South Korea.Naunyn-Schmiedeberg's archives of pharmacology · 2022Article
- Dapsone, More than an Effective Neuro and Cytoprotective Drug.Current neuropharmacology · 2022Review
- Specific Treatment Exists for SARS-CoV-2 ARDS.Vaccines · 2021Article
- Licensed Anti-Microbial Drugs Logical for Clinical Trials against Pathogens Currently Suspected in Alzheimer's Disease.Antibiotics (Basel, Switzerland) · 2021Article
- Progress in the Mechanism of Autophagy and Traditional Chinese Medicine Herb Involved in Dementia.Frontiers in pharmacology · 2021Review
- Warm, Sweetened Milk at the Twilight of Immunity - Alzheimer's Disease - Inflammaging, Insulin Resistance,Frontiers in immunology · 2021Review
- 4,4'-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor.International journal of molecular sciences · 2020Article
- Protective Effects of Dapsone on Scopolamine-Induced Memory Impairment in Mice: Involvement of Nitric Oxide Pathway.Dementia and geriatric cognitive disorders extraArticle
- Commentary for the Elderly in the Pandemic Era.Dementia and geriatric cognitive disorders extraArticle
- The Neuroinflammasome in Alzheimer's Disease and Cerebral Stroke.Dementia and geriatric cognitive disorders extraArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIM/
backgroundThis research aims to prevent progression from mild cognitive impairment (MCI) to Alzheimer's disease. A Japanese study of leprosy patients revealed that the incidence of dementia in leprosy patients was lower than that in patients taking dapsone who had never been treated. But a similar study the following year refuted the finding of less dementia in leprosy patients taking dapsone. According to conflicting reports,
methodsThis is a prospective cohort research. We report on an elderly patient diagnosed with MCI from February 2008 to January 2019. The patient took dapsone 100 mg once a day from 2010 to 2015 for the treatment of MCI. Since 2016, the production of dapsone has ceased in Korea. In June 2018, the patient was diagnosed with Alzheimer's disease. The patient took Aricept for the treatment of Alzheimer's disease but complained of serious side effects. And dapsone was re-administered to the patient from November 2018.
resultsThe patient recovered to MCI and improved her daily life owing to the treatment with dapsone. The drug controls the inflammatory response in the brain, irrespective of whether proteins are deposited in neurons.
conclusionsThis finding means that dementia syndrome is an inflammatory disease. This research suggests that diagnostic criteria for Alzheimer's disease should be based on the presence or absence of inflammation in neurons. Because inflammation in neurons can occur in middle age due to various causes, we can treat inflammation in neurons and prevent and treat dementia syndrome, including Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.